github link
Accession IconGSE48906

Neoadjuvant anastrozole alone or with gefitinib in early breast cancer

Organism Icon Homo sapiens
Sample Icon 94 Downloadable Samples
Technology Badge Icon Affymetrix Human Genome U133 Plus 2.0 Array (hgu133plus2)

Submitter Supplied Information

Description
Trial 223 was a placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. We used patients from arm B and C: anastrozole 1mg/d for the duration of the 16 week period plus placebo 1 tablet/d orally for 2 weeks. Patients in arm B were followed by gefitinib 250mg/d orally for 14 weeks whereas patients in arm C continued with placebo for 14 weeks.
PubMed ID
No associated PubMed ID
Publication Title
No associated publication
Total Samples
96
Submitter’s Institution
Authors
No associated authors

Samples

Show of 0 Total Samples
Filter
Add/Remove
Accession Code
Title
Sex
Processing Information
Additional Metadata
No rows found
Loading...